home / stock / apre / apre news

APRE News and Press, Aprea Therapeutics Inc. From 12/11/19

Stock Information
Company Name: Aprea Therapeutics Inc.
Stock Symbol: APRE
Market: NASDAQ
Website: aprea.com
Menu
APRE APRE Quote APRE Short APRE News APRE Articles APRE Message Board
Get APRE Alerts

News, Short Squeeze, Breakout and More Instantly...
APRE - Aprea adds to APR-246-stoked rally, shares up 17%

Relatively recent IPO Aprea Therapeutics ( APRE +17.2% ) is up on average volume, a modest 127K shares, adding to its breakout after a data presentation on lead candidate APR-246 at ASH on Monday. More news on: Aprea Therapeutics, Inc., Healthcare stocks news, Stocks on the move, R...
APRE - Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annu

74% ORR, 66% CR rate in 24 evaluable MDS patients Median duration of follow-up is 6.4 months BOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that re...

APRE - Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual

88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients 8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients 52% of evaluable MDS patients discontinued treatment for stem cell transplant BOSTON, Dec. 09, 2019 (GLOBE NEWSWIR...

Previous 10 Next 10